Microexons Go Big  by Yang, Li & Chen, Ling-Ling
Leading Edge
PreviewsMicroexons Go BigLi Yang1,* and Ling-Ling Chen2,3,*
1Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology; CAS Center for Excellence in Brain
Science
2State Key Laboratory of Molecular Biology, Shanghai Key Laboratory of Molecular Andrology, Institute of Biochemistry and Cell Biology
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
3School of Life Science and Technology, ShanghaiTech University, Shanghai, 200031, China
*Correspondence: liyang@picb.ac.cn (L.Y.), linglingchen@sibcb.ac.cn (L.-L.C.)
http://dx.doi.org/10.1016/j.cell.2014.12.004
Microexons are frequently underestimated in transcriptome analyses. Two studies published inCell
and Genome Research now independently report the identification of hundreds of microexons.
Alternative splicing of some microexons is regulated by neuronal-specific RNA-binding proteins
andmodifies the function of proteins involved in neurogenesis, with misregulation linked to autism.Nearly all human multi-exonic genes un-
dergo alternative splicing (AS) to produce
more than onematuremRNA, thus greatly
expanding transcriptomic complexity and
functional diversity (Nilsen and Graveley,
2010). Precise annotation of all AS events
is essential for better understanding this
repertoire under both physiological and
pathological conditions, but the combina-
torial aspect of this problem has been a
major challenge. This problem is exacer-
bated in the case of microexons, exons
less than 51 nt, which have often been
overlooked because their short length
makes them computationally difficult to
identify. Microexons are thought to be un-Figure 1. Alternatively Spliced Microexons Are Often Included dur-
ing Neurogenesis along with the Expression of Neural-Specific
Splicing Factors
Neural-specific microexons generally possess weak genomic features for
splicing, such as unfavorable 30 splice sites, which leads to skipping at early
stages of neuronal differentiation (left). During neurogenesis, some neuronal-
specific splicing regulators, such as nSR100, become highly expressed and
are recruited to intronic splicing enhancer regions near suboptimal 30 splice
sites to promote inclusion of microexons. Inclusion leads to the addition of
small numbers of amino acid residues in their protein products, which can alter
protein-protein interactions (right).favorable for splicing because
they lack sufficient exonic
splicing enhancers and they
are so short that the splicing
machinery cannot physically
assemble at both the 30 and
50 splice sites (Black, 1991;
Blencowe, 2000; Fairbrother
et al., 2002). Individual studies
in mammals reported an
important role for microexons
in the brain (Carlo et al., 2000;
Zibetti et al., 2010), but the
wider role of microexons and
the rules governing their
splicing have remained un-
clear. Now, two independent
papers by Irimia et al. (2014)
in this issue of Cell and by Li
et al. (2015) in Genome
Research uncover hundreds
of highly conserved microex-
ons from RNA-seq data sets
across species, outline the1488 Cell 159, December 18, 2014 ª2014 Elsfeatures regulating the inclusion of these
microexons, and show that many of these
impact neurogenesis and brain function.
To assess the contribution of microex-
ons to the transcriptome, Irimia et al.
(2014) develop a multi-module analysis
pipeline to systematically define all neu-
ral-regulated AS patterns, especially
microexons with very short lengths (3–
15 nt), from more than 100 different hu-
man and mouse cell and tissue types.
They show that the regulation of microex-
ons is highly dynamic during neuronal dif-
ferentiation (Figure 1). Strikingly, although
microexons represent only 1% of AS
observed, they constitute up to one-thirdevier Inc.of all conserved neural-regulated AS be-
tween human and mouse. The inclusion
in the final transcript of most identified
neural microexons is regulated by a
brain-specific factor, nSR100, which
binds to intronic enhancer UGC motifs
close to the 30 splice sites. Of particular in-
terest, these microexons are enriched for
lengths that are multiples of 3 nt and are
thus highly likely to produce alternative
protein isoforms if included or excluded
from the final transcript. The authors
further provide several lines of evidence,
both computational and experimental, to
demonstrate that inclusion of microexons
can modulate the function of interactiondomains of proteins involved
in neurogenesis (Figure 1).
Interestingly, misregulation of
neural-specific AS microex-
ons is observed in individuals
with autism spectrum disor-
der (ASD).
Li et al. (2015) approach the
issue in a different way. They
treat microexons as insertions
between annotated splice
junctions to retrieve a set of
microexons that are shorter
than 51 nt, including both
constitutively spliced (CS)
and AS microexons, from
more than 900 human and
mouse samples, nearly half of
whichwere frombrain tissues.
The authors find that AS mi-
croexons are evolutionarily
conserved and exhibit tissue-
specific inclusion. Further-
more, they show that AS of
microexons mediated by specific RNA-
binding proteins (RBPs), such as RBFox
and PTBP1, may alter protein sequences,
thus leading to changes in protein-protein
interactions.
In contrast to CS microexons that
possess strong cis elements to enhance
splicing (Li et al., 2015), AS microexons
require additional interactions with the
splicing machinery, which are usually
enhanced by RBPs. Interestingly, many
brain-specific microexons might be regu-
lated by a single RBP acting as a master
splicing regulator. For instance, Irimia
et al. (2014) demonstrate that neural-spe-
cific factor nSR100 promotes the AS of
very short microexons during neurogene-
sis (Figure 1), and Li et al. (2015) confirm
that most brain-specific microexons are
enhanced by tissue-specific RBFox pro-
teins. It is noteworthy that RBFox1-
dependent AS has been implicated in
ASD (Voineagu et al., 2011). These two
new reports focus on different trans-
acting factors, and questions remain,
including the extent of the overlap of
these two data sets and whether these
distinct splicing regulators act indepen-
dently or in concert to regulate AS of
microexons in the brain. In addition, it
will be of interest to identify other RBPs
or master RBPs that can regulate AS
microexons in different tissues or under
different conditions.
Beyond the discovery of these surpris-
ing rules for the regulation of microexonsplicing, it is of particular significance
that these two studies (Irimia et al., 2014;
Li et al., 2015) demonstrate that alterna-
tive inclusion of microexons generates
proteins with altered functions in neuro-
genesis. Whereas many microexons
introduce short stretches of amino acids
that alter protein-protein interactions,
others may introduce novel charged
regions or new platforms for post-
translational modification. Not all lead
necessarily to changes on the protein sur-
face—one might envision that some mi-
croexon AS results in subtle alterations
in protein folding or catalytic function.
Furthermore, microexons can change
the properties of the mRNA, altering its
structure, stability, or subcellular location.
Given the myriad ways that microexons
can exert their influence, it is likely that
they may have tissue-specific functions
in other organs, and their mis-regulation
may correlate with disease, as was
observed for neuronal-specific microex-
ons and ASD (Irimia et al., 2014). Also,
as neural-specific microexon splicing is
highly conserved during evolution at
both the levels of genomic sequence
and tissue-specific inclusion pattern (Iri-
mia et al., 2014; Li et al., 2015), it will be
of interest to study how selection acts
on microexons. Together, these reports
of the identification and impact of micro-
exons demonstrate the feasibility of
computationally probing transcriptome
for previously hidden information andCell 159, Debegin to outline the mechanisms used
by the cell to achieve the rich complexity
of protein-protein interactions that govern
tissue-specific processes.
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